Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with raltitrexed-based therapy for advanced primary liver cancer
ChiCTR1900023114Phase 4Recruiting
- Sponsor
- Guigang People's Hospital
- Start
- May 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, raltitrexed and oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Guigang People's Hospital. Primary endpoint: progression-free survival. Started May 2019; status: recruiting.
02
Drugs
Rivoceranibraltitrexedoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900023114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023114.